Avantect Ovarian Cancer Test
Cell-free DNA blood LDT intended as an aid to earlier ovarian-cancer detection in women at elevated risk.
- Developer
- ClearNote Health
- Intended use
- Early Detection
- Cancer scope
- Not reported
- Specimen
- Peripheral whole blood
- Molecular modality
- DNA methylation, Multi-omics
- Current version
- Avantect Ovarian Cancer Test current configuration (2026)
- Evidence context
- 0 structured studies · 0 indexed performance results · 1 sources
Why can reported performance numbers differ? MDI keeps each result attached to its study, population, stage or stratum, test version and source rather than treating performance as a fixed property of the test.